NR 576 Week 7 Assignment; Clinical Practice Guidelines; Benign Prostatic Hyperplasia Paper Transcript
-
$20.00
| Institution | Chamberlain |
| Contributor | Maggio |
Benign Prostatic Hyperplasia
Disease & Background
- Identifies the disease condition.
- Gives a brief statement of incidence and prevalence in the US.
- The student briefly summarizes the disease pathophysiology.
- Identifies the typical clinical presentation seen in a patient with the disease
Applicability in Primary Care
- Identifies the author, organization or group that developed the CPG
- Student denotes the year of the original guideline publication
- Student identifies any subsequent revisions (student’s reference should be the most recent version)
- Student discusses the applicability for use of this CPG in the primary care setting
Key Action Statements & Body of Evidence
- Provides each of the CPG’s “Key Action” or “Guideline Statements” up to a maximum of 5 relevant recommendations
Provides the body of evidence strength for each
Initial Evaluation (Guideline Statement 1)
Follow-up Evaluation (Guideline Statement 3)
Alpha Blockers (Guideline Statement 10)
5-Alpha Reductase Inhibitor (5-ARI)(Guideline Statement 13)
Phosphodiesterase-5 Inhibitor (PDE5) (Guideline Statement 17)
Application in Clinical
- Using an example of a patient from their clinical rotation with the same condition
- Student discusses how the diagnosis and treatment of their patient compared to the recommendations given in the guidelines
- Specific examples of what was done well or what could have been done better is noted
| Instituition / Term | |
| Term | Fall Semester |
| Institution | Chamberlain |
| Contributor | Maggio |
